Plasma metabolism marker for early diagnosis or prediction of gestational diabetes and application

By screening plasma metabolic markers such as L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine deoxycholic acid, and combining LC-MS detection and multivariate statistical analysis, the problem of early diagnosis of gestational diabetes mellitus has been solved, achieving efficient early diagnosis and prediction, and improving the diagnostic accuracy of gestational diabetes mellitus.

CN122084906APending Publication Date: 2026-05-26PEKING UNION MEDICAL COLLEGE HOSPITAL
3 Cites 0 Cited by

Patent Information

Application Number
CN202610181544.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-09
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

In current technology, the diagnosis of gestational diabetes is mainly carried out in the second trimester, which may lead to missed opportunities for early intervention, increase the risk of adverse maternal and fetal outcomes, and lack effective methods for early diagnosis or prediction.

Method used

Using plasma metabolic markers such as L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine deoxycholic acid, and by LC-MS detection, combined with multivariate statistical analysis and receiver operating characteristic curves, a model for early diagnosis or prediction of gestational diabetes was constructed.

Benefits of technology

It improves the early diagnosis rate of gestational diabetes mellitus, enhances the accessibility of disease prognosis management, and has clinical application and promotion value. The AUC value of a single biomarker is greater than 0.6, and the AUC value of multiple biomarkers can reach 0.987, which significantly improves the diagnostic accuracy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of diagnosis and detection, and aims to solve the problems that some potential hyperglycemia pregnant women cannot be found and managed in time and the bad outcome risk of mothers and children is increased due to the fact that an existing gestational diabetes mellitus screening mode may miss the optimal opportunity of early intervention. The invention provides a plasma metabolism marker for early diagnosis or prediction of gestational diabetes and application of the plasma metabolism marker. The plasma metabolism marker is at least one of L-lysine, propyl glycine, N6-acetyl-L-lysine, cycloleucine and glycodeoxycholic acid. The five plasma metabolism markers provided by the invention can be applied to early diagnosis or prediction of gestational diabetes mellitus, and are of great significance to prevention or treatment of gestational diabetes mellitus.
Need to check novelty before this filing date? Find Prior Art